ArticleCureus2025
Quality of Life in Patients With Scabies.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Scabies is a common parasitic skin infection that causes significant morbidity worldwide, particularly in resource-limited settings like Pakistan. Despite its prevalence, the psychosocial and quality of life (QoL) impact of scabies is often under-recognized in routine clinical care. This study aimed to determine the impact of scabies on the QoL in patients presenting to a tertiary care hospital in Peshawar. A cross-sectional study was conducted at the Department of Dermatology, Postgraduate Medical Institute (PGMI)/Lady Reading Hospital, Peshawar, between August 2023 and February 2024. A total of 164 patients aged 15-50 years with clinically diagnosed scabies were enrolled. QoL was assessed using the Modified Dermatology Life Quality Index (mDLQI), and scores were categorized into no, mild, moderate, or severe effect. Of 164 patients, 26 (15.9%) reported no effect on QoL, 35 (21.3%) mild, 54 (32.9%) moderate, and 49 (29.9%) severe effect. Overall, 62.8% experienced moderate to severe impairment. Scabies significantly affects patients' QoL, and routine QoL assessment should be incorporated into dermatologic management to address both physical and psychosocial aspects of the disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.